Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer (HRPC) and Rising Prostate Specific Antigen (PSA) Levels Who Have Not Received Prior Chemotherapy

NCT00286806 is registered in ClinicalTrials.gov with Ascenta Therapeutics as lead sponsor.

NCT NCT00286806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00286806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer (HRPC) and Rising Prostate Specific Antigen (PSA) Levels Who Have Not Received Prior Chemotherapy
Lead sponsor
Ascenta Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2005
Completion date
June 30, 2007
Enrollment
27
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hormone refractory prostate cancer